BCTXZ
BriaCell Therapeutics Corp. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.63
52W High
$1.18
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to pioneering immunotherapies for cancer, with a primary focus on breast cancer treatment. Its lead candidate, Bria-IMT, has demonstrated encouraging efficacy in early clinical trials, underscoring the company's commitment to addressing substantial unmet medical needs in oncology. Backed by a strong research and development infrastructure and an experienced leadership team, BriaCell is well-positioned to drive significant innovations in cancer therapeutics and enhance patient outcomes in a dynamic market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-30.63M |
| Operating Margin | 0.00% |
| Return on Equity | -179.20% |
| Return on Assets | -89.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.26 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $6.41M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
138.83%
HV 20-Day
133.52%
HV 30-Day
158.07%
HV 60-Day
199.14%
HV Rank
—
Volatility is currently contracting
Data last updated: 5/5/2026